IDXX Idexx Laboratories Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
06:14
Aug 05
Aug 05
Author long IDEXX from recent lows
Buy IDEXX Laboratories; author discloses an active long position entered from recent lows over the past few weeks, maintaining a cautiously bullish stance within a hedged portfolio framework.
MED
12:30
Aug 04
Aug 04
Management raised full-year organic revenue and EPS guidance midpoint, citing continued strong recurring revenue momentum, innovation traction (InViewDX, CancerDx, Catalyst menu), and planned investments in international commercial expansion.
HIGH
13:30
Feb 12
Feb 12
Management notes that US owner economics are being squeezed by escalating veterinary clinic prices, which is driving a decline in routine care visits and accelerating a shift toward emergency/urgent care and value-focused, alternative care models. — A structural slowdown in routine veterinary visits in the US could dampen the volume of products sold through traditional clinics, pressuring companies with high US companion-animal exposure and shifting demand toward retail/online channels and urgent care centers.
MED
13:30
Feb 02
Feb 02
Management's guidance for 2026 is positive, expecting 7-9% organic revenue growth and 10-14% EPS growth, driven by continued innovation adoption and commercial execution despite macro headwinds.
HIGH
About IDXX Analyst Coverage
Buzzberg tracks IDXX (Idexx Laboratories) across 3 sources. 1 bullish vs 0 bearish calls from 4 analysts. Sentiment: predominantly bullish (20%). 5 total trade ideas tracked. Past 7 days: 1 bullish, 1 watch. Latest voices: asklivermore, Andrew Emerson, tacticzh.